E. Liu

发表

Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma

Erin F. Simonds, Leo D. Wang, P. Walker, 2021, Journal for ImmunoTherapy of Cancer.

Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

L. Coussens, M. Tempero, C. Lopez, 2023, Journal for ImmunoTherapy of Cancer.

Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer

P. Sharma, E. Small, J. Allison, 2021, Journal for ImmunoTherapy of Cancer.

Deep immune profiling reveals targetable mechanisms of immune evasion in checkpoint blockade-refractory glioblastoma

Erin F. Simonds, Leo D. Wang, P. Walker, 2020, bioRxiv.

Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy

L. Fong, T. Beer, M. Stein, 2020, Frontiers in Oncology.

Clonal Deletion of Tumor‐Specific T Cells by Interferon‐&ggr; Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade

D. M. Simons, Kole T. Roybal, R. Sachidanandam, 2019, Immunity.

The impact of prior radiation therapy on outcome in a phase 2 trial combining sipuleucel-T (SipT) and ipilimumab (Ipi) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).

P. Sharma, E. Small, J. Allison, 2021 .

A pilot phase Ib study to evaluate tadalafil to overcome immunosuppression during chemoradiotherapy for IDH-wild-type glioblastoma

Omar H. Butt, D. Hallahan, M. Chheda, 2023, Neuro-oncology advances.

Immune modulatory effects of ibrutinib in pancreatic ductal adenocarcinoma.

L. Coussens, M. Tempero, L. Fong, 2019, Annals of Oncology.